Galectin Therapeutics Inc. Insider Trading
GALT
Insiders bought 65K and sold $2.94M on the open market.
All of the selling was scheduled in advance under 10b5-1 plans.
Get an email when GALT's executives or directors buy, or make a large sale outside a plan.
Trades · last 2 years
| Date | Insider | Trade | Shares | Price | Value | Of their stake | Filing |
|---|---|---|---|---|---|---|---|
| Jul 14 | Khurram Jamil Chief Medical Officer | Sold10b5-1 plan | 16,250 | $5.13 | 83K | 100% | Form 4 |
| Jun 26 – 29 | Harold H. Shlevin Director | Sold10b5-1 plan 2 parts | 30,000 | $5.03 average | 151K | 82% | Form 4 |
| Jun 26 – 29 | Khurram Jamil Chief Medical Officer | Sold10b5-1 plan 3 parts | 52,037 | $5.04 average | 262K | 100% | Form 4 |
| Jun 23 | Khurram Jamil Chief Medical Officer | Sold10b5-1 plan | 7,557 | $3.14 | 24K | 100% | Form 4 |
| May 26 | Khurram Jamil Chief Medical Officer | Sold10b5-1 plan | 568 | $3.10 | 2K | 100% | Form 4 |
| Feb 6 | Kary Eldred Director | Bought | 300 | $2.70 | $810 | 0.4% | Form 4 |
| Jan 2 – 6 | Joel Lewis President and CEO | Sold10b5-1 plan 3 parts | 84,000 | $3.83 average | 321K | 9.1% | Form 4 |
| Jan 2 – 6 | Jack W Callicutt Chief Financial Officer | Sold10b5-1 plan 3 parts | 60,000 | $3.89 average | 233K | 89% | Form 4 |
| Jan 2 – 6 | Khurram Jamil Chief Medical Officer | Sold10b5-1 plan 3 parts | 60,000 | $3.88 average | 233K | 100% | Form 4 |
| Dec 31, 2025 | Khurram Jamil Chief Medical Officer | Sold10b5-1 plan | 8,125 | $4.07 | 33K | 100% | Form 4 |
| Dec 23, 2025 | Kevin D Freeman Director | Bought | 5,500 | $3.55 | 20K | 3.7% | Form 4 |
| Dec 23, 2025 | Kevin D Freeman Director | Bought | 5,500 | $3.55 | 20K | 4.2% | Form 4 |
| Dec 23, 2025 | Kevin D Freeman Director | Bought | 5,500 | $3.55 | 20K | 4.2% | Form 4 |
| Dec 23, 2025 | Kary Eldred Director | Bought | 700 | $3.73 | 3K | 1.0% | Form 4 |
| Dec 23, 2025 | Kary Eldred Director | Bought | 700 | $3.73 | 3K | 1.0% | Form 4 |
| Dec 17, 2025 | Joel Lewis President and CEO | Sold10b5-1 plan | 7,829 | $7.06 | 55K | 0.9% | Form 4 |
| Dec 17, 2025 | Khurram Jamil Chief Medical Officer | Sold10b5-1 plan 3 parts | 19,442 | $7.04 average | 137K | 100% | Form 4 |
| Dec 17, 2025 | Harold H. Shlevin Director | Sold10b5-1 plan 2 parts | 24,499 | $7.04 average | 172K | 79% | Form 4 |
| Dec 16, 2025 | James C Czirr Large holder | SoldNo plan | 30,681 | $6.66 | 204K | 0.5% | Form 4 |
| Dec 12, 2025 – Dec 15, 2025 | Harold H. Shlevin Director | Sold10b5-1 plan 2 parts | 28,210 | $6.28 average | 177K | 48% | Form 4 |
| Dec 8, 2025 – Dec 9, 2025 | Harold H. Shlevin Director | Sold10b5-1 plan 8 parts | 175,790 | $6.00 average | $1.06M | 94% | Form 4 |
| Dec 2, 2025 – Dec 3, 2025 | 10X Capital Management, LLC Large holder | SoldNo plan 2 parts | 162,069 | $5.68 average | 921K | 2.8% | Form 4 |
| Nov 17, 2025 – Nov 18, 2025 | Joel Lewis President and CEO | Sold10b5-1 plan 2 parts | 22,463 | $6.07 average | 136K | 2.6% | Form 4 |
| Nov 17, 2025 – Nov 18, 2025 | Jack W Callicutt Chief Financial Officer | Sold10b5-1 plan 5 parts | 77,920 | $6.14 average | 479K | 91% | Form 4 |
| Nov 13, 2025 | Khurram Jamil Chief Medical Officer | Sold10b5-1 plan 4 parts | 121,117 | $5.47 average | 663K | 96% | Form 4 |
| Nov 11, 2025 | 10X Capital Management, LLC Large holder | SoldNo plan | 40,000 | $5.25 | 210K | 0.7% | Form 4 |
| Nov 10, 2025 | Joel Lewis President and CEO | Sold10b5-1 plan | 1,867 | $6.03 | 11K | 0.2% | Form 4 |
| Nov 10, 2025 | Jack W Callicutt Chief Financial Officer | Sold10b5-1 plan 3 parts | 5,291 | $6.03 average | 32K | 41% | Form 4 |
| Nov 5, 2025 | Joel Lewis President and CEO | Sold10b5-1 plan | 200 | $6.00 | 1K | <0.1% | Form 4 |
| Nov 5, 2025 | Jack W Callicutt Chief Financial Officer | Sold10b5-1 plan 3 parts | 600 | $6.00 average | 4K | 7.3% | Form 4 |
| Nov 3, 2025 – Nov 4, 2025 | Joel Lewis President and CEO | Sold10b5-1 plan 2 parts | 15,720 | $6.07 average | 95K | 1.8% | Form 4 |
| Nov 3, 2025 – Nov 4, 2025 | Jack W Callicutt Chief Financial Officer | Sold10b5-1 plan 6 parts | 32,439 | $6.06 average | 197K | 68% | Form 4 |
| Oct 22, 2025 | 10X Capital Management, LLC Large holder | SoldNo plan 2 parts | 50,000 | $4.94 average | 247K | 0.8% | Form 4 |
| Sep 12, 2025 | Jack W Callicutt Chief Financial Officer | Sold10b5-1 plan | 8,706 | $6.44 | 56K | 53% | Form 4 |
| Sep 12, 2025 | Joel Lewis President and CEO | Sold10b5-1 plan | 14,000 | $6.36 | 89K | 1.6% | Form 4 |
| Jul 21, 2025 | Kary Eldred Director | Bought | 1,000 | $2.93 | 3K | 1.5% | Form 4 |
| Jul 17, 2025 | Kevin D Freeman Director | Bought | 5,000 | $2.90 | 15K | 3.5% | Form 4 |
| Dec 30, 2024 | Harold H. Shlevin Director | Bought | 6,500 | $1.16 | 8K | 75% | Form 4 |
| Dec 24, 2024 | Richard A. Zordani Jr. Director | Bought | 10,000 | $0.82 | 8K | 29% | Form 4 |
| Dec 24, 2024 | Kary Eldred Director | Bought | 13,469 | $0.82 | 11K | 25% | Form 4 |
- Jul 1410b5-1 planKhurram JamilChief Medical Officer · sold 16,250 at $5.1383K100% of stake
- Jun 26 – 2910b5-1 planHarold H. ShlevinDirector · sold 30,000 at avg $5.03151K82% of stake
- Jun 26 – 2910b5-1 planKhurram JamilChief Medical Officer · sold 52,037 at avg $5.04262K100% of stake
- Jun 2310b5-1 planKhurram JamilChief Medical Officer · sold 7,557 at $3.1424K100% of stake
- May 2610b5-1 planKhurram JamilChief Medical Officer · sold 568 at $3.102K100% of stake
- Feb 6Kary EldredDirector · bought 300 at $2.70$8100.4% of stake
- Jan 2 – 610b5-1 planJoel LewisPresident and CEO · sold 84,000 at avg $3.83321K9.1% of stake
- Jan 2 – 610b5-1 planJack W CallicuttChief Financial Officer · sold 60,000 at avg $3.89233K89% of stake
- Jan 2 – 610b5-1 planKhurram JamilChief Medical Officer · sold 60,000 at avg $3.88233K100% of stake
- Dec 31, 202510b5-1 planKhurram JamilChief Medical Officer · sold 8,125 at $4.0733K100% of stake
- Dec 23, 2025Kevin D FreemanDirector · bought 5,500 at $3.5520K3.7% of stake
- Dec 23, 2025Kevin D FreemanDirector · bought 5,500 at $3.5520K4.2% of stake
- Dec 23, 2025Kevin D FreemanDirector · bought 5,500 at $3.5520K4.2% of stake
- Dec 23, 2025Kary EldredDirector · bought 700 at $3.733K1.0% of stake
- Dec 23, 2025Kary EldredDirector · bought 700 at $3.733K1.0% of stake
- Dec 17, 202510b5-1 planJoel LewisPresident and CEO · sold 7,829 at $7.0655K0.9% of stake
- Dec 17, 202510b5-1 planKhurram JamilChief Medical Officer · sold 19,442 at avg $7.04137K100% of stake
- Dec 17, 202510b5-1 planHarold H. ShlevinDirector · sold 24,499 at avg $7.04172K79% of stake
- Dec 16, 2025No planJames C CzirrLarge holder · sold 30,681 at $6.66204K0.5% of stake
- Dec 12, 2025 – Dec 15, 202510b5-1 planHarold H. ShlevinDirector · sold 28,210 at avg $6.28177K48% of stake
- Dec 8, 2025 – Dec 9, 202510b5-1 planHarold H. ShlevinDirector · sold 175,790 at avg $6.00$1.06M94% of stake
- Dec 2, 2025 – Dec 3, 2025No plan10X Capital Management, LLCLarge holder · sold 162,069 at avg $5.68921K2.8% of stake
- Nov 17, 2025 – Nov 18, 202510b5-1 planJoel LewisPresident and CEO · sold 22,463 at avg $6.07136K2.6% of stake
- Nov 17, 2025 – Nov 18, 202510b5-1 planJack W CallicuttChief Financial Officer · sold 77,920 at avg $6.14479K91% of stake
- Nov 13, 202510b5-1 planKhurram JamilChief Medical Officer · sold 121,117 at avg $5.47663K96% of stake
- Nov 11, 2025No plan10X Capital Management, LLCLarge holder · sold 40,000 at $5.25210K0.7% of stake
- Nov 10, 202510b5-1 planJoel LewisPresident and CEO · sold 1,867 at $6.0311K0.2% of stake
- Nov 10, 202510b5-1 planJack W CallicuttChief Financial Officer · sold 5,291 at avg $6.0332K41% of stake
- Nov 5, 202510b5-1 planJoel LewisPresident and CEO · sold 200 at $6.001K<0.1% of stake
- Nov 5, 202510b5-1 planJack W CallicuttChief Financial Officer · sold 600 at avg $6.004K7.3% of stake
- Nov 3, 2025 – Nov 4, 202510b5-1 planJoel LewisPresident and CEO · sold 15,720 at avg $6.0795K1.8% of stake
- Nov 3, 2025 – Nov 4, 202510b5-1 planJack W CallicuttChief Financial Officer · sold 32,439 at avg $6.06197K68% of stake
- Oct 22, 2025No plan10X Capital Management, LLCLarge holder · sold 50,000 at avg $4.94247K0.8% of stake
- Sep 12, 202510b5-1 planJack W CallicuttChief Financial Officer · sold 8,706 at $6.4456K53% of stake
- Sep 12, 202510b5-1 planJoel LewisPresident and CEO · sold 14,000 at $6.3689K1.6% of stake
- Jul 21, 2025Kary EldredDirector · bought 1,000 at $2.933K1.5% of stake
- Jul 17, 2025Kevin D FreemanDirector · bought 5,000 at $2.9015K3.5% of stake
- Dec 30, 2024Harold H. ShlevinDirector · bought 6,500 at $1.168K75% of stake
- Dec 24, 2024Richard A. Zordani Jr.Director · bought 10,000 at $0.828K29% of stake
- Dec 24, 2024Kary EldredDirector · bought 13,469 at $0.8211K25% of stake
Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.
Peers
Pharmaceutical Preparations · Pick stocks to compare with GALT
Held by ETFs
GALT is in 5 US ETFs. The largest of them, with GALT's weight in each:
Spot a number that looks wrong? Check it in GALT's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing GALT
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.